Posted by admin on Jul 23rd, 2022
Comerica Bank lessened its position in shares of Teleflex Incorporated (NYSE:TFX – Get Rating) by 1.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,417 shares of the medical technology company’s stock after selling 81 shares during the period. Comerica Bank’s holdings in Teleflex were worth $2,567,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the company. Allworth Financial LP raised its position in shares of Teleflex by 144.4% during the 4th quarter. Allworth Financial LP now owns 110 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 65 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teleflex by 62.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 114 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 44 shares during the period. Aquire Wealth Advisors LLC acquired a new stake in shares of Teleflex during the 4th quarter worth approximately $38,000. Spire Wealth Management raised its position in shares of Teleflex by 3,900.0% during the 4th quarter. Spire Wealth Management now owns 120 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 117 shares during the period. Finally, Ten Capital Wealth Advisors LLC acquired a new stake in shares of Teleflex during the 4th quarter worth approximately $43,000. Institutional investors own 92.21% of the company’s stock.
Shares of NYSE TFX opened at $265.18 on Friday. The firm has a market cap of $12.44 billion, a P/E ratio of 25.77, a PEG ratio of 1.72 and a beta of 1.17. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.53 and a current ratio of 2.28. The stock has a fifty day moving average price of $265.10 and a two-hundred day moving average price of $303.54. Teleflex Incorporated has a 1 year low of $235.58 and a 1 year high of $405.97.
Teleflex (NYSE:TFX – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The medical technology company reported $2.88 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.15. The business had revenue of $641.70 million during the quarter, compared to analyst estimates of $631.89 million. Teleflex had a return on equity of 17.24% and a net margin of 17.31%. The company’s revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company posted $2.87 EPS. Research analysts forecast that Teleflex Incorporated will post 13.96 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 15th. Stockholders of record on Monday, May 16th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. The ex-dividend date was Friday, May 13th. Teleflex’s dividend payout ratio is presently 13.22%.
In related news, Director Stuart A. Randle sold 3,014 shares of the company’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $283.31, for a total transaction of $853,896.34. Following the transaction, the director now directly owns 4,320 shares of the company’s stock, valued at $1,223,899.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.28% of the stock is currently owned by insiders.
TFX has been the topic of a number of research reports. Morgan Stanley dropped their price target on Teleflex from $343.00 to $300.00 and set an “equal weight” rating on the stock in a research report on Friday, July 15th. Truist Financial lowered their target price on Teleflex to $270.00 in a research report on Friday. TheStreet cut Teleflex from a “b-” rating to a “c+” rating in a research report on Monday, May 16th. Royal Bank of Canada lowered their target price on Teleflex from $390.00 to $380.00 in a research report on Monday, May 23rd. Finally, Wolfe Research assumed coverage on Teleflex in a research report on Tuesday, July 5th. They issued an “outperform” rating and a $300.00 target price on the stock. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $368.77.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX – Get Rating).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
Sumitomo Mitsui Trust Holdings Inc. Has $130,000 Stock Position in Creative Media & Community Trust Co. (NASDAQ:CMCT)
Sumitomo Mitsui Trust Holdings Inc. Buys New Position in SPDR Portfolio Intermediate Term Corporate Bond ETF (NYSEARCA:SPIB)